Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Operating Income of $19.60 million for fiscal year 2025.
ELITE PHARMACEUTICALS INC /NV/ Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $19.60M | +81.7% |
| 2024 | $10.79M | +193.5% |
| 2023 | $3.68M | -27.5% |
| 2022 | $5.07M | +140.9% |
| 2021 | $2.10M | +192.1% |
| 2020 | -$2.29M | +75.0% |
| 2019 | -$9.16M | -1.2% |
| 2018 | -$9.05M | -23.0% |
| 2017 | -$7.36M | +11.6% |
| 2016 | -$8.32M | +49.6% |
| 2015 | -$16.51M | -212.4% |
| 2014 | -$5.28M | -238.0% |
| 2013 | -$1.56M | +20.5% |
| 2012 | -$1.97M | -122.0% |
| 2011 | -$885.8K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $9.01M | +721.0% | +9.7% |
| September 30, 2025 | $8.21M | +135.7% | -62.1% |
| June 30, 2025 | $21.70M | +461.6% | +1876.6% |
| December 31, 2024 | $1.10M | -68.9% | -68.5% |
| September 30, 2024 | $3.48M | +81.0% | -9.8% |
| June 30, 2024 | $3.86M | +141.2% | +9.4% |
| December 31, 2023 | $3.53M | +80.3% | +83.5% |
| September 30, 2023 | $1.93M | +78.1% | +20.2% |
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +81.7% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, ELITE PHARMACEUTICALS INC /NV/’s operating income has grown by 2312.8% (from -$885.8 thousand to $19.60 million).
- The most recent figure is from ELITE PHARMACEUTICALS INC /NV/’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: